logo

For the Inventor, By the Inventor

Danville, CA, United States of America

Andreas Sommer

This inventor holds 8 USPTO granted patents. Top assignees: Celtrix Pharmaceuticals, Inc., Amgen Inc., University of Colorado. Active years: 1995-2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas Sommer. Retrieved from https://idiyas.com/inventor/andreas-sommer-k1k7dods

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 140(Granted Patents)


Location History:

  • Pleasanton, CA (US) (2000)
  • Concord, CA (US) (1995 - 2003)
  • Danville, CA (US) (1998 - 2005)

Company Filing History:

goldMedal6 out of 45 
 
Celtrix Pharmaceuticals, Inc.
 patents
silverMedal1 out of 2,072 
 
Amgen Inc.
 patents
bronzeMedal1 out of 1,449 
 
University of Colorado
 patents
4. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1995-2005

Loading Chart...
8 patents (USPTO):Explore Patents
1. 6858409 - Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors (2005-02-22),
2. 6599873 - Interleukin-1 inhibitors, compositions, and methods of treatment (2003-07-29),
3. 6124259 - Method for treating ophthalmic disorders with IGFBP (2000-09-26),
4. 6040292 - Methods for treating diabetes (2000-03-21),
5. 5948757 - High dose IGF-1 therapy (1999-09-07),
6. 5789547 - Method of producing insulin-like growth factor-I (IGF-I) and (1998-08-04),
7. 5643867 - Method for treating catabolic conditions (1997-07-01),
8. 5407913 - Method and composition for systemic treatment of tissue injury (1995-04-18),

Title: Innovations of Andreas Sommer in Interleukin-1 Inhibitors

Introduction

Andreas Sommer is a notable inventor based in Danville, California, with a significant contribution to the field of biochemistry. He holds a total of 8 patents, showcasing his innovative work in developing interleukin-1 inhibitors. His research has the potential to impact therapeutic approaches for various inflammatory conditions.

Latest Patents

Sommer's latest patents include groundbreaking work on nucleic acids encoding interleukin-1 inhibitors and processes for preparing these inhibitors. The compounds he has developed are characterized by the general formula R—X—R, where R and R represent biologically active groups, at least one of which is polypeptidic. The non-peptidic polymeric group X plays a crucial role in the functionality of these compounds. His patents also cover site selectively modified interleukin-1 receptor antagonists and 30 kDa TNF inhibitors, which are essential for advancing treatment methodologies.

Career Highlights

Throughout his career, Sommer has worked with various organizations, including Celtrix Pharmaceuticals, Inc. His experience in the pharmaceutical industry has allowed him to translate his innovative ideas into practical applications that can benefit patients.

Collaborations

Sommer has collaborated with notable professionals in his field, including Charles H. Hannum and Robert C. Thompson. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

Andreas Sommer's contributions to the field of interleukin-1 inhibitors demonstrate his commitment to innovation and improving healthcare outcomes. His patents reflect a deep understanding of biochemistry and a dedication to developing effective treatments for inflammatory diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…